Eli Lilly, the "King of Medicine," hits another record high! JPMorgan raises Eli Lilly's target price! (In-depth)

Eli Lilly (LLY) shares reached a new high on July 8, 2026, with the most direct catalyst beingWall Street investment bank JPMorgan's significant post-market target price raise on July 7.

I. Core Catalyst: JPMorgan Raises Target Price

JPMorgan analyst Chris Schott raised Eli Lilly’s target price from$1,300 to $1,400, maintaining an “Overweight” rating. This target price is significantly higher than Wall Street’s average of $1,243, implying about a17% upside from the July 6 closing price.

The analyst report clearly states the bullish thesis for Eli Lilly is based on:

• Sustained volume growth for Mounjaro in international markets

• Steady growth in the U.S. obesity market

• Estimatedtotal sales this quarter will reach $20.7 billion (about $300 million higher than consensus),EPS of $8.85 (up $0.13)

II. Other Positive Views from Wall Street Banks

Before JPMorgan, other banks had already released positive signals:

Cantor Fitzgerald specifically noted that large biopharma companies are expected to report overall strong results for Q2 2026 and may drive several companies to raise their full-year revenue guidance.

III. Strong Growth Expectations for the GLP-1 Product Line

Investment bank reports commonly emphasize that Eli Lilly's growth momentum comes from itsGLP-1 weight-loss drug product line:

• Zepbound (obesity indication) maintains steady demand in the U.S.

• Mounjaro (diabetes indication) continues to expand in international markets

• Oral medication orforglipron (Foundayo) andtriple agonist retatrutide and other next-generation assets are still raising market expectations

IV. Recent Additional Positive Factors

Over the past few weeks, Eli Lilly has also accumulated several favorable developments:

1. U.S. Medicare GLP-1 Bridge Program: Starting July 1, 2026, eligible insured participants are provided access to Zepbound and Foundayo for only $50/month out-of-pocket, which is expected to significantly broaden patient access

2. Cancer drug Jaypirca receives European support: EMA’s Committee for Medicinal Products for Human Use supports its use in chronic lymphocytic leukemia, paving the way for final EU approval

3. Sector rotation effect: On July 8, funds rotated from semiconductor stocks to healthcare, with Eli Lilly, as a sector leader, seeing notable benefits

V. Fundamental Data Support

From a fundamental perspective, Eli Lilly’s share price has risen about54%-58% over the past year, with a market capitalization reaching$1.1 trillion. The company’s revenue rose by 47%, its PEG ratio is only 0.33, and its Piotroski score reached a perfect 9, reflecting strong financial health.

Summary: The record high in Eli Lilly’s share price is a direct result ofJPMorgan’s significant target price upgrade, combined withmultiple positive calls from investment banks,strong growth expectations for the GLP-1 product line,several recent positive developments, andsector rotation. The market will closely monitor theQ2 earnings report to be released in August (UTC+8), to verify whether the investment bank forecasts (sales of $20.7 billion, EPS $8.85) materialize.